Alcon axes eye program

Alcon announced late Friday that it was ending its evaluation of anecortave acetate for age-related macular degeneration. The Swiss company says that an analysis of the data demonstrated no effect on the primary or secondary endpoints. Release | Report

Suggested Articles

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.